Stockreport

Palisade Bio: Undervalued Biotech With Blockbuster Potential, Initiating With A Speculative Buy Rating [Seeking Alpha]

Palisade Bio, Inc.  (PALI) 
PDF PALI-2108's phase 1 data show promising efficacy, mechanistic engagement, and improved tolerability versus systemic PDE4 inhibitors, supporting further development. P [Read more]